Search Results
Search for other papers by Britt B M Suelmann in
Google Scholar
PubMed
Search for other papers by Carmen van Dooijeweert in
Google Scholar
PubMed
Search for other papers by Carsten F J Bakhuis in
Google Scholar
PubMed
Search for other papers by Sabine Linn in
Google Scholar
PubMed
Search for other papers by Elsken van der Wall in
Google Scholar
PubMed
Search for other papers by Paul J van Diest in
Google Scholar
PubMed
Introduction Breast cancer is the most common type of invasive cancer among pregnant women ( Smith et al. 2003 ) and has been reported to affect 1 in 3000 to 10,000 pregnancies ( Antonelli et al. 1996 , Loibl et al. 2006 ). The average
University College Cork, Medicine, Cork, Ireland
Search for other papers by Conleth G Murphy in
Google Scholar
PubMed
Joan and Sanford I Weill Medical College of Cornell University, Medicine, New York, New York, USA
Search for other papers by Maura N Dickler in
Google Scholar
PubMed
Introduction Approximately 70% of advanced breast cancers are considered ‘hormone responsive’ as defined by expression of the estrogen receptor (ER), progesterone receptor (PR), or both. Various thresholds have been proposed for the level of
Search for other papers by Ton van Agthoven in
Google Scholar
PubMed
Search for other papers by Anieta M Sieuwerts in
Google Scholar
PubMed
Search for other papers by Danielle Meijer in
Google Scholar
PubMed
Search for other papers by Marion E Meijer-van Gelder in
Google Scholar
PubMed
Search for other papers by Thecla L A van Agthoven in
Google Scholar
PubMed
Search for other papers by Roya Sarwari in
Google Scholar
PubMed
Search for other papers by Stefan Sleijfer in
Google Scholar
PubMed
Department of Pathology, Cancer Genomics Center
Search for other papers by John A Foekens in
Google Scholar
PubMed
Search for other papers by Lambert C J Dorssers in
Google Scholar
PubMed
Introduction Estrogens play important roles in the establishment and progression of breast cancer. As a consequence, endocrine treatment modalities have been designed to counter the supportive role of estrogens in breast cancer. In the past
Search for other papers by Shyh-Han Tan in
Google Scholar
PubMed
Search for other papers by Marja T Nevalainen in
Google Scholar
PubMed
, Kindblom et al . 2002 , 2003 ). Autocrine PRL in prostate and breast tissue became important findings, since local production of PRL provided an explanation as to why the results of studies trying to link breast or prostate cancer incidence or progression
Search for other papers by R Kaaks in
Google Scholar
PubMed
Search for other papers by S Rinaldi in
Google Scholar
PubMed
Search for other papers by T J Key in
Google Scholar
PubMed
Search for other papers by F Berrino in
Google Scholar
PubMed
Search for other papers by P H M Peeters in
Google Scholar
PubMed
Search for other papers by C Biessy in
Google Scholar
PubMed
Search for other papers by L Dossus in
Google Scholar
PubMed
Search for other papers by A Lukanova in
Google Scholar
PubMed
Search for other papers by S Bingham in
Google Scholar
PubMed
Search for other papers by K-T Khaw in
Google Scholar
PubMed
Search for other papers by N E Allen in
Google Scholar
PubMed
Search for other papers by H B Bueno-de-Mesquita in
Google Scholar
PubMed
Search for other papers by C H van Gils in
Google Scholar
PubMed
Search for other papers by D Grobbee in
Google Scholar
PubMed
Search for other papers by H Boeing in
Google Scholar
PubMed
Search for other papers by P H Lahmann in
Google Scholar
PubMed
Search for other papers by G Nagel in
Google Scholar
PubMed
Search for other papers by J Chang-Claude in
Google Scholar
PubMed
Search for other papers by F Clavel-Chapelon in
Google Scholar
PubMed
Search for other papers by A Fournier in
Google Scholar
PubMed
Search for other papers by A Thiébaut in
Google Scholar
PubMed
Search for other papers by C A González in
Google Scholar
PubMed
Search for other papers by J R Quirós in
Google Scholar
PubMed
Search for other papers by M-J Tormo in
Google Scholar
PubMed
Search for other papers by E Ardanaz in
Google Scholar
PubMed
Search for other papers by P Amiano in
Google Scholar
PubMed
Search for other papers by V Krogh in
Google Scholar
PubMed
Search for other papers by D Palli in
Google Scholar
PubMed
Search for other papers by S Panico in
Google Scholar
PubMed
Search for other papers by R Tumino in
Google Scholar
PubMed
Search for other papers by P Vineis in
Google Scholar
PubMed
Search for other papers by A Trichopoulou in
Google Scholar
PubMed
Search for other papers by V Kalapothaki in
Google Scholar
PubMed
Search for other papers by D Trichopoulos in
Google Scholar
PubMed
Search for other papers by P Ferrari in
Google Scholar
PubMed
Search for other papers by T Norat in
Google Scholar
PubMed
Search for other papers by R Saracci in
Google Scholar
PubMed
Search for other papers by E Riboli in
Google Scholar
PubMed
Introduction Most of the established epidemiological risk factors for breast cancer are related to alterations in endogenous hormone metabolism ( Pike et al . 1993 , Russo & Russo 1999 , Russo et al . 2000 , Key et al . 2001
Search for other papers by Teeranut Asavasupreechar in
Google Scholar
PubMed
Department of Pathology, National Hospital Organization, Sendai Medical Center, Sendai, Miyagi, Tōhoku, Japan
Search for other papers by Ryoko Saito-Koyama in
Google Scholar
PubMed
Search for other papers by Yasuhiro Miki in
Google Scholar
PubMed
Search for other papers by Keiichi Tamai in
Google Scholar
PubMed
Search for other papers by Jiro Abe in
Google Scholar
PubMed
Search for other papers by Chihiro Inoue in
Google Scholar
PubMed
Search for other papers by Ikuro Sato in
Google Scholar
PubMed
Search for other papers by Viroj Boonyaratanakornkit in
Google Scholar
PubMed
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
Introduction Sex steroid hormones and their receptors are well known to play important roles in breast cancer progression. Progesterone receptor (PR) has two main isoforms, PR isoform A (PRA) and PR isoform B (PRB), in human tissues ( Conneely
Search for other papers by Yuanzhong Wang in
Google Scholar
PubMed
Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan, Republic of China
Search for other papers by Yen-Dun Tony Tzeng in
Google Scholar
PubMed
Search for other papers by Gregory Chang in
Google Scholar
PubMed
Search for other papers by Xiaoqiang Wang in
Google Scholar
PubMed
Search for other papers by Shiuan Chen in
Google Scholar
PubMed
Introduction Approximately 70% breast cancers are estrogen receptor positive (ER+), and endocrine therapy is the main treatment for ER+ breast cancer patients. Selective ER modulators (e.g. tamoxifen) and aromatase inhibitors (AIs) constitute
Search for other papers by S Rinaldi in
Google Scholar
PubMed
Search for other papers by P H M Peeters in
Google Scholar
PubMed
Search for other papers by F Berrino in
Google Scholar
PubMed
Search for other papers by L Dossus in
Google Scholar
PubMed
Search for other papers by C Biessy in
Google Scholar
PubMed
Search for other papers by A Olsen in
Google Scholar
PubMed
Search for other papers by A Tjonneland in
Google Scholar
PubMed
Search for other papers by K Overvad in
Google Scholar
PubMed
Search for other papers by F Clavel-Chapelon in
Google Scholar
PubMed
Search for other papers by M C Boutron-Ruault in
Google Scholar
PubMed
Search for other papers by B Téhard in
Google Scholar
PubMed
Search for other papers by G Nagel in
Google Scholar
PubMed
Search for other papers by J Linseisen in
Google Scholar
PubMed
Search for other papers by H Boeing in
Google Scholar
PubMed
Search for other papers by P H Lahmann in
Google Scholar
PubMed
Search for other papers by A Trichopoulou in
Google Scholar
PubMed
Search for other papers by D Trichopoulos in
Google Scholar
PubMed
Search for other papers by M Koliva in
Google Scholar
PubMed
Search for other papers by D Palli in
Google Scholar
PubMed
Search for other papers by S Panico in
Google Scholar
PubMed
Search for other papers by R Tumino in
Google Scholar
PubMed
Search for other papers by C Sacerdote in
Google Scholar
PubMed
Search for other papers by C H van Gils in
Google Scholar
PubMed
Search for other papers by P van Noord in
Google Scholar
PubMed
Search for other papers by D E Grobbee in
Google Scholar
PubMed
Search for other papers by H B Bueno-de-Mesquita in
Google Scholar
PubMed
Search for other papers by C A Gonzalez in
Google Scholar
PubMed
Search for other papers by A Agudo in
Google Scholar
PubMed
Search for other papers by M D Chirlaque in
Google Scholar
PubMed
Search for other papers by A Barricarte in
Google Scholar
PubMed
Search for other papers by N Larrañaga in
Google Scholar
PubMed
Search for other papers by J R Quiros in
Google Scholar
PubMed
Search for other papers by S Bingham in
Google Scholar
PubMed
Search for other papers by K T Khaw in
Google Scholar
PubMed
Search for other papers by T Key in
Google Scholar
PubMed
Search for other papers by N E Allen in
Google Scholar
PubMed
Search for other papers by A Lukanova in
Google Scholar
PubMed
Search for other papers by N Slimani in
Google Scholar
PubMed
Search for other papers by R Saracci in
Google Scholar
PubMed
Search for other papers by E Riboli in
Google Scholar
PubMed
Search for other papers by R Kaaks in
Google Scholar
PubMed
) have been published on the relationship between total IGF-I and IGFBP-3 concentrations in blood and breast cancer ( Renehan et al . 2004 , Shi et al . 2004 , Sugumar et al . 2004 , Fletcher et al . 2005 ), which indicated an overall increase in
Search for other papers by Marina Brama in
Google Scholar
PubMed
Search for other papers by Sabrina Basciani in
Google Scholar
PubMed
Search for other papers by Sara Cherubini in
Google Scholar
PubMed
Search for other papers by Stefania Mariani in
Google Scholar
PubMed
Search for other papers by Silvia Migliaccio in
Google Scholar
PubMed
Search for other papers by Mario Arizzi in
Google Scholar
PubMed
Search for other papers by Giuseppe Rosano in
Google Scholar
PubMed
Search for other papers by Giovanni Spera in
Google Scholar
PubMed
Search for other papers by Lucio Gnessi in
Google Scholar
PubMed
KL/c-kit in breast neoplasias. KL and c-kit are high in normal mammary gland, significantly lower in in situ and almost completely undetectable in invasive breast cancer ( Ulivi et al. 2004 , Yared et al. 2004 ). Breast carcinoma is known to
Search for other papers by K S Kimbro in
Google Scholar
PubMed
Search for other papers by J W Simons in
Google Scholar
PubMed
-inducible factor 1 (HIF-1) complex. HIF-1 is involved in the cancer biology of many endocrine tumors. This review will concentrate on endocrine oncology: HIF-1 in breast cancer and prostate cancer, specifically. New data on HIF-1 signaling and the potential for